Valor202020212022202320242025TTMFlujo de caja de las actividades de inversión-493 K-82 K-759 K-160 K-4.11 M-854 K-854 KFlujo de caja de las actividades financieras-319 K20.42 M13.45 M3.44 M6.19 M30.31 M30.31 MFlujo de caja libre-8.83 M-10.28 M-12.97 M-12.85 M-11.24 M-20.84 M-20.84 M
PLUS THERAPEUTICS Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.